Lusedra is owned by Eisai Inc.
Lusedra contains Fospropofol Disodium.
Lusedra has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lusedra are:
Lusedra was authorised for market use on 12 December, 2008.
Lusedra is available in solution;intravenous dosage forms.
Lusedra can be used as sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation.
The generics of Lusedra are possible to be released after 01 July, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6204257||EISAI INC||Water soluble prodrugs of hindered alcohols|| |
(9 months ago)
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
Market Authorisation Date: 12 December, 2008
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic